BJP MLA slams Serum India over anti-COVID vaccine pricing, calls its CEO Adar Poonawalla ”dacoit”
PTI, Apr 22, 2021, 5:18 PM IST
Lucknow: Upset over anti-coronavirus vaccine pricing by the Serum Institute of India (SII), a BJP MLA has compared its CEO Adar Poonawalla with a “dacoit” and asked the government to “acquire” the company under the Epidemic Diseases Act.
Gorakhpur MLA Radha Mohan Das Agrawal made the remarks after SII on Wednesday announced a price of Rs 600 per dose for Covishield supplies to private hospitals and Rs 400 per dose to state governments.
“@adarpoonawalla you are worse than a dacoit. @PMOIndia @AmitShah @blsanthosh @drharshvardhan should acquire your factory under the epidemic act,” the MLA, who is also a doctor, said in a tweet in Hindi on Wednesday.
In a series of tweets, Agrawal also referred to the Swaminathan Commission’s formula for agriculture costs and prices.
The world’s largest vaccine maker announced the pricing of AstraZeneca shots it manufactures at its Pune facility, following the government decision to open up inoculation to all citizens above 18 years of age.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
PM Modi leaves for home after concluding three-nation visit
Actress Kasthuri released from jail, says ‘I thank those who made me raging storm’
Kerala HC quashes FIR against Goa Guv over remarks on Sabarimala women entry
Smriti Irani embarks on four-nation tour to promote book on PM Modi
Karnataka Milk Federation enters Delhi-NCR, offers competitive pricing on Nandini products
MUST WATCH
Latest Additions
‘Bengaluru Chalo’ protest demand rejection of Kasturirangan Report
Mangaluru: Cyber frauds posing as TRAI representatives fleece Rs 1.71 crore
10 month baby gets new heart, new life
Saura Swasthya launched: Karnataka to power 5,000 health facilities with solar energy
India-US ties have strong foundation: White House confident in navigating crisis over Adani bribery charges
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.